Bladder cancer drug ($IBRX) in final FDA approvals just given green light by Saudi equivalent of FDA

Original Reddit post

Author holds ImmunityBio (IBRX) long, citing Saudi FDA-equivalent approval for its bladder cancer drug and sees large upside.

IBRX — LONG The author has held ImmunityBio for about five years and re-accumulated around $10, arguing the company's bladder cancer drug just received a green light from Saudi Arabia's FDA equivalent. He frames the regulatory approval as a catalyst driving recent gains (up 29% in a day, 67% in a week) and sees substantial upside still below the 2021 $30 high. The main stated risk is that he is still down overall on his position after an earlier snag the CEO resolved.

Bladder cancer drug ($IBRX) in final FDA approvals just given green light by Saudi equivalent of FDA